Tag: SUD

SUDA Pharmaceuticals ASX SUD TGA approval ZolpiMist adult insomnia treatment

SUDA Pharmaceuticals receives TGA approval for ZolpiMist adult insomnia treatment

Perth-based SUDA Pharmaceuticals (ASX: SUD) has received approval from the Therapeutic Goods Administration for its ZolpiMist oral spray to be used in the treatment of short-term adult insomnia. Th...
Suda Pharmaceuticals ASX SUD paediatric consumer market product Laboratorios Ordesa

Suda Pharmaceuticals to co-develop paediatric consumer market product with Laboratorios Ordesa

A novel product for the consumer paediatric market could soon be developed after drug delivery specialist Suda Pharmaceuticals (ASX: SUD) announced a fully-funded feasibility study and option agreemen...
Suda Pharmaceuticals ASX SUD Oromist technology Oral spray medicinal cannabis formula

SUDA Pharmaceuticals inks deal with Cann Pharmaceutical to develop medical cannabis oral spray

Drug delivery specialist SUDA Pharmaceuticals (ASX: SUD) has finalised a deal with medical cannabis company Cann Pharmaceutical Australia that will see the pair develop an oro-mucosal spray to treat d...
SUDA Pharmaceuticals ASX SUD licensing deal Mitsubishi Tanabe Pharma ZolpiMist

SUDA signs licensing deal with Mitsubishi Tanabe Pharma for Asian sales of ZolpiMist

Perth-based SUDA Pharmaceuticals (ASX: SUD) has entered into an exclusive licence agreement with Mitsubishi Tanabe Pharma Singapore Pte Ltd for sales of its ZolpiMist anti-insomnia oral spray in the A...
SUDA Pharmaceuticals Zelda Therapeutics ASX SUD ZLD medicinal cannabis oral spray

SUDA Pharmaceuticals and Zelda Therapeutics to develop novel medicinal cannabis oral spray

Drug delivery specialist company SUDA Pharmaceuticals (ASX: SUD) has unveiled a deal with Zelda Therapeutics (ASX: ZLD) in the form of a fully funded feasibility and option agreement. The agreement...
Suda Pharmaceuticals ASX SUD migraine Strides Pharma Global United States

Suda Pharmaceuticals’ migraine treatment to hit US market

Suda Pharmaceuticals (ASX: SUD) is set to commercialise its SUD-001H migraine spray in the United States after securing an agreement with Strides Pharma Global. Suda has developed a fast-acting ora...